ArticleLeukemia2012
Actinomycin D induces p53-independent cell death and prolongs survival in high-risk chronic lymphocytic leukemia.
Article in Leukemia, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 32 citations in OpenAlex.
- Developing an antibody drug encapsulation nanoagent targeting HER2 for cancer treatment.Journal of translational medicine · 2026Article
- Pervasive environmental contaminant acrolein compromises myocardial geometry and function through the induction of cuproptosis.Acta biochimica et biophysica Sinica · 2025Article
- Anticancer drug response prediction integrating multi-omics pathway-based difference features and multiple deep learning techniques.PLoS computational biology · 2025Article
- Preclinical Assessment of Dactinomycin inCancers · 2025Article
- Diversity and antimicrobial activity of the tropical ant-derived actinomycetes isolated from Thailand.AIMS microbiology · 2024Article
- Synergistic binding of actinomycin D and echinomycin to DNA mismatch sites and their combined anti-tumour effects.Nucleic acids research · 2023Article
- Biosensor-based active ingredient recognition system for screening TNF-α inhibitors from lotus leaves.Analytical and bioanalytical chemistry · 2023Article
- Context-dependent activation of p53 target genes and induction of apoptosis by actinomycin D in aerodigestive tract cancers.Apoptosis : an international journal on programmed cell death · 2022Article
- Article
- New phenoxazinone-related alkaloids from strain Streptomyces sp. KIB-H1318.The Journal of antibiotics · 2018Article
- Neutral metalloaminopeptidases APN and MetAP2 as newly discovered anticancer molecular targets of actinomycin D and its simple analogs.Oncotarget · 2018Article
- Potent anti-leukemic activity of a specific cyclin-dependent kinase 9 inhibitor in mouse models of chronic lymphocytic leukemia.Oncotarget · 2018Article
- Inhibition of neurotensin receptor 1 induces intrinsic apoptosis via let-7a-3p/Bcl-w axis in glioblastoma.British journal of cancer · 2017Article
- Effect of low doses of actinomycin D on neuroblastoma cell lines.Molecular cancer · 2016Article
- The long journey of TCL1 transgenic mice: lessons learned in the last 15 years.Gene expression · 2015Review
- Actinomycin D inhibits cell proliferations and promotes apoptosis in osteosarcoma cells.International journal of clinical and experimental medicine · 2015Article
- The crucial role of divalent metal ions in the DNA-acting efficacy and inhibition of the transcription of dimeric chromomycin A3.PloS one · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic lymphocytic leukemia (CLL) is the most prevalent lymphoid malignancy in the elderly of the Western world. Although treatment options have improved over the past two decades, 10-15% of patients still have a poor prognosis and are often resistant to therapy. Aberrations in the p53 pathway, such as a deleted (del17p13) or mutated p53 gene, are highly enriched in this class of patients. In an extensive screen for p53-independent apoptosis inducers, actinomycin D was identified from 1496 substances and shown to induce apoptosis in primary CLL cells derived from high-risk patients including those with aberrant p53, revealing a novel p53-independent mechanism of action. Both pro-survival genes BCL2 and MCL1 are targeted by actinomycin D, in contrast to fludarabine the backbone of current treatment schedules. In the well-established TCL1 transgenic mouse model for high-risk CLL, actinomycin D treatment was more effective in reducing tumor load than fludarabine, with no evidence of resistance after three treatment cycles and an overall survival increase of over 300%. Tumor load reduction was coupled to BCL2 downregulation. Our results identify the clinically approved compound actinomycin D as a potentially valuable treatment option for CLL high-risk patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.